Introduction
During the process of endochondral bone formation, chondrocytes and osteoblasts are believed to mineralize their extracellular matrix by promoting the initial formation of crystalline hydroxyapatite (HA) in the sheltered interior of membrane-limited matrix vesicles (MVs).
(1) This is followed by the modulation of matrix composition to further promote propagation of apatite outside of the MVs. (2, 3) Regulation of this biphasic two-step mineralization process depends on a regulated balance of a number of factors such as Ca 2+ and inorganic phosphate (P i ) concentrations, the presence of matrix proteins and of adequate mineralization inhibitors including inorganic pyrophosphate (PP i ), matrix gla protein and osteopontin. (4) (5) (6) (7) (8) Three osteoblast molecules have been identified as affecting the controlled deposition of bone mineral by regulating the extracellular levels of PP i , and in turn of osteopontin, i.e., tissuenonspecific alkaline phosphatase (TNAP); NPP1 (a nucleotide pyrophosphatase/phosphodiesterase isozyme) and the ANK gene product. (9) (10) (11) (12) (13) (14) (15) (16) (17) In bone, TNAP is confined to the cell surface of osteoblasts and chondrocytes, including the membranes of their shed MVs. (18, 19) It has been proposed that the role of TNAP in bone matrix is to generate P i for HA crystallization. (20) (21) (22) However, TNAP has also been hypothesized to hydrolyze the mineralization inhibitor PP i (4) to facilitate mineral precipitation and growth. (23) (24) (25) A variety of loss-of-function mutations in the human TNAP gene (ALPL) lead to hypophosphatasia, an inborn error-of-metabolism characterized by rickets and osteomalacia. (26) Mice with null mutations in the orthologous Akp2 gene phenocopy infantile hypophosphatasia (27, 28) including elevations in the known substrates of TNAP, i.e., pyridoxal-5'-phosphate and PP i . Electron microscopy revealed that TNAP-deficient MVs, both in patients with hypophosphatasia as well as in Akp2 -/-mice, contain apatite crystals, but that 6 extravesicular crystal propagation is retarded. (29, 30) This crystal growth retardation, referred to as the second step of MV-mediated calcification, most likely results from the accumulated levels of PP i in the extracellular matrix as a consequence of the lack of TNAP's pyrophosphatase function and the concomitant pyrophosphate-induced increase in osteoblast production of osteopontin, another potent inhibitor of calcification. (17) But, why are Akp2 -/-mice born with a mineralized skeleton and still contain HA crystals inside their MVs? . TNAP is known to sit on the outer surface of the MV membrane and although it has not been adequately resolved that there is no TNAP inside MVs, it is likely that another enzyme is responsible for either cleaving PP i or elevating the intravesicular concentration of P i so as to achieve a P i /PP i ratio conducive for crystallization.
We have previously proposed that PHOSPHO1, a novel phosphatase, plays the important role of increasing the P i /PP i ratio inside MVs and thus control the first step of HA crystal deposition inside MVs. (31) MVs have long been recognised to contain high levels of Pi. (32) Since its identification in the chicken (33) , PHOSPHO1
orthologues have also been identified in a number of other species including humans, mice and zebrafish. (34, 35) However, to date no information exists on the expression of PHOSPHO1 in the mammalian skeleton. PHOSPHO1, a member of the haloacid dehalogenase superfamily, is localised to mineralizing surfaces in both bone and cartilage of the chicken where its expression precedes the deposition of mineral suggesting that it is involved in the initial events of mineral formation. (31, 36) It is a soluble cytosolic enzyme that has specificity for phosphoethanolamine (PEA) and phosphocholine (PCho) (37, 38) but not for PPi and a number of other potential substrates. (37) PEA and PCho are the two most abundant phosphomonoesters in cartilage. (39) In addition, the proportions of membrane phospholipids containing these groups decrease in MVs during mineralization, whilst 1,2-diacyl glycerol accumulates, indicative of phospholipase C activity. (40) This gives rise to the possibility of a novel mechanism whereby plasma membrane bound phosphate may be released through the action of PHOSPHO1 and phospholipase C to contribute to the P i concentration inside the MV.
The critical first step of mineralization mediates the deposition of the initial crystals of HA. We hypothesize that a TNAP-independent step involves PHOSPHO1
functioning to increase the local concentration of P i inside the MVs. Thus, we would envisage that an inhibition of PHOSPHO1 activity would result in decreased mineralization within MVs. Therefore, to test this hypothesis experimentally we have now examined the expression of PHOSPHO1 in murine mineralizing cells and MVs, screened for and characterized a series of small-molecule PHOSPHO1-specific inhibitors and used these compounds to pharmacologically inhibit the first step of MV-mediated mineralization.
Materials and Methods

Chemical libraries
The 
Recombinant PHOSPHO1
A cDNA corresponding to Met19-Cys267 of human PHOSPHO1 was amplified and cloned into the pBAD TOPO TA vector (Invitrogen) as previously described. (37) Briefly, the construct was designed to express PHOSPHO1 fused to a V5 epitope and 6 His-tag at the C-terminus. A clone containing the PHOSPHO1 fragment in the correct orientation was identified by restriction digestion of plasmid minipreparations. E. coli were grown in Lauria-Bertani broth (10 litres, 37 0 C) and recombinant protein expression was induced by treatment with 0.1% (w/v) Larabonose for 4 h.
Inhibitor Screening
The semi-automated screening utilized a Beckman Coulter dual bridge 
Characterisation of Inhibitors
The IC50 for each inhibitor was determined using the phosphatase assay detailed above. The inhibitor concentration was varied between 100 and 0.3 µM with each individual reaction repeated in triplicate. The data of absorbance vs. inhibitor concentration was plotted using SigmaPlot and four parameter logistic curve fitted.
The IC50 was calculated using the equation; y = min + (max-min/1+ 10 (logEC50-x)Hillslope ). Effect of inhibitors on recombinant mammalian expressed TNAP protein (41) was assessed under optimal conditions; 1M diethanolamine buffer pH 9.6, 1mM pNPP and inhibitor concentrations were varied accordingly. Absorbance's were measured continuously at 405 nm using a VICTOR HTS plate-reader. (37) Immunolocalization of PHOSPHO1 within long bones
Ten-day old male mice were euthenized by cervical dislocation and tibiae were fixed in 4% paraformaldeyde in PBS for 24 h before decalcification in 0.5M EDTA (pH 8.0) for a further 24 h at 4 0 C. The fixed tissue was dehydrated and paraffin embedded using standard techniques. Paraffin sections (6 µm) were dewaxed in xylene and rehydrated through a graded series of alcohol solutions and antigen retrieval was achieved by heating in sodium citrate for 90 minutes at 70 °C followed by extensive washing in PBS. Endogenous peroxidases were blocked by incubating the sections with 3% hydrogen peroxide (in methanol), followed by 3 washes in PBS.
Unspecific protein binding was blocked by normal goat serum ( 
Isolation of MVs from Chick Growth Plate Cartilage
All animal studies and protocols were approved by the Institutional Animal
Users Committees of both Roslin Institute and Burnham Institute for Medical
Research. Under sterile conditions, growth plate cartilage from 3-week-old male broiler chickens was collected and diced. MVs were released by incubating the tissue at 37 °C with 0.45% collagenase (Worthington, type II) in 50mM Tris-HCl pH 7.6, 120 mM NaCl and 10 mM KCl for 3 h with constant agitation. The digested tissue was passed through a 40 µM sieve to remove undigested material. MVs were harvested from the digest by differential centrifugation as previously described. (42) Briefly, the digest was centrifuged for 30 min at 1500 g to collect chondrocytes, then at 30, 000 g to remove sub -cellular debris and finally at 250, 000g to pellet MVs.
Isolation of MVs from primary cultured calvarial osteoblasts
Mouse calvarial cells were isolated from 3-day-old mice through sequential collagenase digestion, as previously described. (11, 16) Calvarial cells from Akp2 -/-,
Akp2
+/-and wild-type mice were pooled separately and plated at a density of 20,000/cm 2 in alpha-MEM (Gibco, Paisley, UK) containing 10% FBS, 50 µg/ml ascorbate for a period of 21 days. The cell monolayer was washed with 50mM TrisHCl pH 7.6, 120 mM NaCl and 10 mM KCl, and then incubated with 0.45% collagenase (Worthington, type II) in 50 mM Tris-HCl pH 7.6, 120 mM NaCl and 10 mM KCl at 37ºC for 120 min at 37ºC, with constant agitation. This cell suspension was subjected to differential centrifugation as described above to isolate both cells and MVs.
MV phosphatase activity and mineralization ability
Phosphatase activity within chick and mouse MVs was determined using the standard discontinuous colorimetric assay. (43) In brief, reactions were measured in 96-well plates containing 200 µl of 25% (w/v) glycerol, 20 mM TBS, pH 7.2, 25 µg/ml BSA, 2.5 mM PEA, 2 mM MgCl 2 and 12 µg MV protein. (37) PHOSPHO1
inhibitors at a final concentration of 1mM were used where appropriate. The mouse MVs were either left intact or ruptured by sonication to release the cytosolic contents.
TNAP activity was determined using the Thermo-line ALP reagent (Melbourne, Australia). Total TNAP activity was expressed as nmoles pNPP hydrolysed/ min/mg protein. The in-vitro calcification ability of MV was determined by their ability to form calcium phosphate in vitro. (44) In brief, samples of MV protein (15µg of chick MVs and 20µg of TNAP null osteoblast derived MVs) were incubated in calcification buffer in the presence of 0 to 3 mM phosphoester substrate for 5.5 h at 37°C. The reaction was terminated by centrifugation at 8800g for 30 minutes to pellet both MVs and any calcium phosphate mineral formed during incubation. The pellet was then solubilised with 0.6N HCl for 24 h and used directly in for calcium quantification using the O-cresolpthalein complexone method (CPC Kit, Thermotrace).
Western Blotting of PHOSPHO1 within MVs
Murine MVs were analysed for the presence of PHOSPHO1 by immunoblotting. MV preparations were lysed in PBS containing 1.6 mg/ml of were carried out and subjected to an identical PCR to allow estimation of PCR efficiency. Relative differences in expression were calculated using the 2 -rCT method.
Semi Quantitative PCR of osteoblast specific genes
Murine osteoblasts (Akp2 -/-and wild-type) were cultured in alpha-MEM containing 10% FBS, 50 µg/ml ascorbate and ß-glycerophosphate (10mmol/L) for up 
Statistical analysis
Analysis of variance (ANOVA) was performed to determine the significance of a given result. General Linear Model analysis incorporating pair-wise comparisons using Tukeys test was used to compare groups within the ANOVA models. All data are expressed as the mean +/-SD. Statistical analysis was performed using Minitab 14. Statistical significance was accepted at P<0.05.
Results
PHOSPHO1 Expression in Whole Tissues
To investigate the levels of PHOSPHO1 gene expression in different mammalian tissues, we used qPCR to obtain relative expression values. Bone had the highest expression levels while the least amount of PHOSPHO1 transcript was found in the liver (Fig. 1) . The difference in expression between these two tissue types was ~120 fold. Furthermore, low transcript levels were detectable in all tissues examined; heart (5.67), bone marrow (3.57), adipose tissue (3.38), brain (1.96) and gut (1.20) (numbers in brackets represent the fold difference when compared to PHOSPHO1 expression in liver, which was arbitrarily set as 1 for comparison).
Immunolocalization of PHOSPHO1 to skeletal cells and Identification of PHOSPHO1 in MVs
15
The high expression level of PHOSPHO1 in bone observed by qPCR was confirmed and extended by the immunolocalization of PHOSPHO1 to primary regions of ossification in both growth plate cartilage and trabecular and cortical bone.
PHOSPHO1 was restricted to the hypertrophic zone of the growth plate (Fig 2a) . No staining was observed in the proliferating chondrocytes and in comparison to the prehypertrophic chondrocytes the terminally differentiated cells displayed little staining.
PHOSPHO1 immunoreactivity was also observed within the chondrocytes of the developing secondary ossification centre (Fig 2b) . 
Identification of Active PHOSPHO1 in MVs
To determine if PHOSPHO1 present in murine MVs was active, we tested for hydrolase activity within intact and sonicated MVs isolated from cultures of Akp2 -/-,
Akp2
+/-and wild-type osteoblasts. This strategy was adopted to eliminate the possibility that TNAP hydrolysis of PEA may mask PHOSPHO1 activity. Cell phenotype was confirmed using ALP histochemistry and mineralization capability by von Kossa staining (data not shown). TNAP activity of intact MVs purified from these cultures mirrored that of TNAP histochemistry (Fig.3a) . MV preparations were used directly in the standard discontinuous colorimetric assay. It was found that the 
Is PHOSPHO1 Expression influenced by the presence of TNAP?
To analyse whether PHOSPHO1 expression was altered by TNAP expression, RNA was extracted from cells cultured for up to 14 days under mineralizing conditions. The TNAP genotype was confirmed by PCR and PHOSPHO1 expression was not altered by the background TNAP status of the cells nor by continuous culture for up to 14-days (Fig. 4) .
Identification and Characterization of PHOSPHO1 Inhibitors
In order to be able to conduct studies to examine the effects of PHOSPHO1 inhibition on MV-mediated calcification, we first needed to identify and characterize small molecule inhibitors specific for PHOSPHO1. Consequently we screened two 
Effect of PHOSPHO1 Inhibitors on MV Phosphatase Activity
With these novel inhibitors at hand, we used chick MV protein directly as a source of wild-type PHOSPHO1 in a discontinuous colorimetric assay to assess the effect of inhibiting PHOSPHO1 activity on P i generation. Each inhibitor was used at a concentration of 1 mM. The uninhibited MV protein exhibits a PEA hydrolase activity of 87.1 ± 1.8 nmol min -1 mg -1 whereas in the presence of Lansoprazole and SCH202676 this activity was reduced to 62.9 ± 1.1 nmol min -1 mg -1 and 73.0 ± 2.7 nmol min -1 mg -1 respectively (Fig. 6a) . In comparison to the uninhibited reactions these activities relate to a reduction in activity of approximately 28% for Lansoprazole (P<0.001) and 16% for SCH202676 (P<0.001). Neither Lansoprazole nor SCH202676 interfered with the ability of TNAP to catalyse the hydrolysis of pNPP under optimal conditions, but did exhibit inhibition of PHOSPHO1 mediated hydrolysis of pNPP similar to that seen when using PEA as a substrate (Fig. 6b) .
Effect of PHOSPHO1 Inhibitors on MV Calcification
Using the in vitro calcification assay we found that PEA supports the calcification of chick MVs, purified from growth plate cartilage, comparable to that shown by the phosphoester ß-glycerophosphate, 1.0 ± 0.01 and 1.3 ± 0.04 units of precipitated calcium (Fig. 7a) . Chick MVs preparations were subsequently incubated with 1mM
of Lansoprazole or SCH202676 which resulted in a slight decrease in calcifying potential in the presence of PEA (approximately 10% with each inhibitor (P<0.001), (Fig. 7b) .
To increase the sensitivity of this assay the inhibitor actions were examined on MVs extracted from cultured Akp2 -/-osteoblasts. This strategy eliminated the possibility of TNAP hydrolysing the phosphoester and potentially masking the effects of the PHOSPHO1 inhibitors. Using this strategy, a much more pronounced inhibitory effect was seen with Lansoprazole and SCH202676. In comparison to uninhibited reactions, Lansoprazole exhibited a 56.8 % inhibition of calcification (P<0.01) whereas SCH202676 inhibited calcification by 70.7% (P<0.001) (Fig 7c) .
Discussion
The mechanisms and proteins regulating matrix mineralization are not yet fully understood, and we are still unclear if under physiological conditions mineralization is due to the presence of promoters of mineralization (active process) or a lack of mineralization inhibitors (passive process). (45) Notwithstanding the presence of an optimum balance of both inhibitors and promoters, the mineralization process is clearly dependent on the attainment of sufficiently high concentrations of P i for the formation of de novo calcium phosphate crystals. Generation of P i for mineralization has long been attributed to the actions of TNAP (6, 20) but it is now clear that the production of Pi for matrix calcification is not entirely attributable to TNAP activity.
In newborn Akp2 knockout mice, bone development and mineralization appear normal even though hypomineralization and other abnormalities do subsequently appear. (11, 27, 28) Although mechanisms involving in utero protection cannot be ruled out the postnatal mineralization defects in Akp2 -/-mice are likely to be due to a build up of PP i , a known substrate of TNAP (21) and a potent inhibitor of HA crystal formation. (4) Indeed, hypomineralization is greatly reduced in [Akp2 -/-; Enpp1 -/-] double-knockout mice where extracellular PP i (ePP i ) concentrations return to normal after ablating NPP1 enzyme activity, i.e., the enzyme that produces PP i at the surface of osteoblasts and MVs. (10, 11) Hypomineralization in these double knockout mice is corrected in a site-specific manner in the calvaria and vertebrae while residual hypomineralization remains in metatarsals and long bones. (6) Mechanistically, the aforementioned build-up of ePP i in Akp2-/-mice in turn leads to upregulated osteopontin expression by Akp2-/-osteoblasts (17) and it has recently been shown that it is the combined accumulation of ePP i and OPN that causes osteomalacia in Akp2-/-mice. (17) The location of TNAP to the outer surface of MV membrane and the demonstrated role of this enzyme as a pyrophosphatase in vivo suggests that other molecules or mechanisms are responsible for increasing intravesicular P i levels so as to achieve a P i /PP i ratio conducive for crystallization. The sodium-dependent phosphate type III transporter Pit-1 (GLvr-1) (46) (47) (48) and other phosphatases such as, pyrophosphatase, AMPase and ATPase, known to be present in MVs (6, 49, 50) may be involved. In this present study we now provide the first functional evidence that PHOSPHO1 is a MV phosphatase involved in skeletal mineralization.
The immunolocalization of PHOSPHO1 in the mouse is consistent with its presumed role in matrix mineralization. PHOSPHO1 was localized in chondrocytes 20 in the early hypertrophic zone of the growth plate and to bone forming surfaces in both long bones (trabecular and cortical) and the site of the developing secondary ossification centre. This distribution, together with the absence of strong PHOSPHO1 immunoreactivity in the hypertrophic chondrocytes situated deep in the mineralized zone, suggests that PHOSPHO1 has a pivotal role in the initial stages of the mineralization process and is required for the de novo formation of the inorganic phase but not for the continued crystal growth of hydroxyapatite. This concurs with studies of the developing chick skeleton, where the expression of PHOSPHO1 in the mid-shaft of long bones preceded alizarin red staining, indicative of calcium deposition. (31) This localisation of PHOSPHO1 to bone forming surfaces mirrors that of TNAP (51, 52) , and perhaps indicates synergy between the two enzymes to achieve HA crystal growth. Although likely working in concert, no evidence was obtained to suggest that PHOSPHO1 expression was influenced by the presence/absence of TNAP possibly indicating that PHOSPHO1 is functioning independently from TNAP.
The matrix staining of PHOSPHO1 on bone forming surfaces is likely to reflect the presence of the enzyme in osteoblast derived MVs, which are deposited within newly formed osteoid. (53) Indeed the presence of PHOSPHO1 in MVs derived from calvarial osteoblasts was confirmed by immunoblotting as was the ability of TNAP null MV lysates to catalyse the hydrolysis of PEA. This indicates that the enzyme responsible for this degradation is cytosolic and, as according to the KEGG database (54) only TNAP and PHOSPHO1 have the ability to cleave PEA, it is likely that this cytosolic enzyme is in fact PHOSPHO1.
The high expression of PHOSPHO1 in bone noted by qPCR is consistent with the immunolocalization of PHOSPHO1, however, its low basal expression in a number of soft tissues may indicate other putative roles for this enzyme. Phosphocholine is an important regulatory compound for the metabolism of phosphatidylcholine, the major phospholipid in mammalian tissues. (55) In heart muscle it has been documented that the PCho pool is much lower than that in the liver or HeLa Cells (56) , however the enzyme responsible for this hydrolysis remains unknown. (57) It is interesting to speculate that this step may be controlled by the PCho activity of PHOSPHO1 (37, 38) thereby explaining the low expression in the heart and implicating PHOSPHO1 in a possible novel pathway which may be mediated by one of the alternate transcript from the PHOSPHO1 gene. Lansoprazole and SCH 202676 decreased the amount of liberated P i using isolated chick MV by 28% and 16% respectively. Ebselen has no effect on PEA hydrolase activity of MVs thus it is likely that this inhibitor is not effective against the wild-type enzyme. As this is a non-competitive inhibitor and binds at a site distinct from the active site, it is conceivable that Ebselen is binding recombinant PHOSPHO1 at the C terminal tagged region thus inhibiting the recombinant but not the wild-type enzyme. SCH 202676 is a thiadiazole compound that acts upon and inhibits signalling through G protein-coupled receptors. (58) It is thought that this compound is an allosteric modulator of G protein-coupled receptors and may recognise an intracellular regulatory domain of the protein, however it's exact mode of inhibition remains unknown. (59) In contrast, Lansoprazole is an extremely wellcharacterised compound. This drug belongs to a class of compounds known as the 2- converted into an acid activated cationic sulphenamide form (AG2000) which acts as a proton pump inhibitor (60) , blocking the final step of acid production.
The effect of Lansoprazole and SCH 202676 on P i release by chick MVs was greater than their inhibitory effect on MV calcification which was only ~10% with each inhibitor. This imbalance is possibly due to TNAP activity of the MVs preparations masking the effects of the PHOSPHO1 inhibitors by promoting PP i hydrolysis and/or maintaining P i levels at about the minimum threshold for mineralization to occur normally. Alternatively, preformed mineral crystals found within MVs may be acting as local nucleators allowing mineral propagation, even in the presence of PHOSPHO1 inhibitors. To avoid interference from TNAP in the assay system, we used MVs isolated from calvaria of TNAP null mice. In this case a more profound inhibition was observed; SCH 202676 and Lansoprazole caused a 71 and 57% decrease in calcification, respectively. This indicates that PHOSPHO1 which is sequestered within the lumen of the MV has the ability to hydrolyse PEA to increase the intravesicular concentrations of P i to allow mineralization to occur. This is likely to occur in synergy with phosphate (46) (47) (48) and calcium (61) (62) (63) transporters to facilitate the production of the initial crystals for hydroxyapatite deposition. SCH202676 is an allosteric antagonist of dopamine receptors and Lansoprazole is a proton pump inhibitor, and both are already being used in the treatment of patients, however to the best of our knowledge their use has not been reported to be associated with rickets or osteomalacia.
In conclusion the Phospho1 gene is highly expressed in bone tissue and the PHOSPHO1 protein localization is restricted to sites of skeletal mineralization in the mouse. Further, PHOSPHO1 protein is cytosolic and active within murine osteoblastderived MVs retaining the ability to hydrolyse the PEA, as previously demonstrated with the recombinant enzyme. (37, 38) In addition, the PHOSPHO1 inhibitors SCH 202676 and Lansoprazole have the ability to modulate the in vitro mineralization of MVs. These data further strengthens the hypothesis that PHOSPHO1 has a role in bone mineralization, likely to be linked to the glycerolipid metabolism pathways involving the degradation of phosphatidylethanolamine and phosphatidylcholine and the production of P i for MV mediated mineralization. 
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